Table 2 Diverse types of nanoparticles
From: Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
Type | Discovery Time | Size (nm) | Advantage | First delivery | First delivery time | References |
|---|---|---|---|---|---|---|
Polymeric nanoparticles | Unknown | 1–1000 | Good drug stability; | Abraxane | 2005 | (Aghebati-Maleki et al. 2020) |
Good endothelial permeability; | ||||||
Accurate localization at tumor tissues | ||||||
Liposomes | 1961 | Varies with composition | Protection from degradation; | Doxil | 1995 | (Almeida et al. 2020) |
Reducing drug toxicity; | ||||||
Biocompatibility; | ||||||
Proper targeting | ||||||
Gold nanoparticles | 1857 | 3–200 | Optical and electronic properties; | TNF | 2004 | (Paciotti et al. 2004) |
Stable | ||||||
Quantum dots | 1980 | 4–12 | Small size; | Captopril | 2006 | (Wang and Chen 2011) |
Light stable and fluorescent | ||||||
Dendrimers | 1985 | 2–10 | High drug loading capacity; | Vivagel | 2007 | (Kim et al. 2018) |
Surface modifications possible; | ||||||
Correctly targeting specific tissues or cells | ||||||
Carbon Nanotubes | 1976 | 0.4–100 | Stability and flexibility; | EPO | 2005 | (Saito et al. 2009) |
High ability to penetrate cell membranes; | ||||||
High drug loading capacity |